Tokyo, Nov. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059900) titled 'Microsatellite Instability (MSI) Screening Study for Resectable Solid Tumors (Excluding Colorectal Cancer)' on Nov. 27.

Study Type: Observational

Primary Sponsor: Institute - National Cancer Center Hospital East

Condition: Condition - Malignant solid tumors Classification by malignancy - Malignancy Genomic information - YES

Objective: Narrative objectives1 - To clarify the frequency of high-frequency microsatellite instability (MSI-H) in resectable solid tumors (excluding colorectal cancer) and the patient background according to MSI status. Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1)Untreated malignant tumors confirmed by histopathological diagnosis 2)Age 18 years or older 3)Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 4)Cannot be expected to achieve cure with local therapy using endoscopy, cystoscopy, etc. 5)Is a locally advanced solid cancer (excluding colorectal cancer) expected to achieve cure with surgical resection, radiation therapy, or chemoradiation therapy 6)Tumor tissue specimens can be submitted to this study Key exclusion criteria - 1)Presence of distant metastatic lesions 2)Clinical diagnosis of carcinoma in situ or mucosal carcinoma 3)Diagnosis of active concomitant cancer *Lesions corresponding to carcinoma in situ or mucosal carcinoma deemed curable by local therapy are not included in active concomitant cancer 4)Severe concomitant diseases (e.g., poorly controlled diabetes, infections, symptomatic interstitial pneumonia, pulmonary fibrosis, etc.) 5)Lack of willingness to participate in the study 6)If the attending physician determines the patient is not suitable for enrollment in this study Target Size - 5000

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2025 Year 05 Month 08 Day Date of IRB - 2025 Year 07 Month 10 Day Anticipated trial start date - 2025 Year 07 Month 24 Day Last follow-up date - 2027 Year 12 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068392

Disclaimer: Curated by HT Syndication.